SCHEMBL22993306

SCHEMBL22993306

OCc1ccc2c(c1)CCOC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 2/20 0.38
PRMT5 O14744 2/20 0.36
WDR77 Q9BQA1 2/20 0.36
NAMPT P43490 4/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
P2RX3 P56373 1/20 0.33
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA7 P36544 1/20 0.32
CA12 O43570 1/20 0.32
CA2 P00918 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32
CA5A P35218 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
CA5B Q9Y2D0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21382554 0.93 PRMT5 (0.40) GRIN2BPRMT5WDR77NAMPTCYP4F2
SCHEMBL1466786 0.84 CA12 (0.35) GRIN2BNAMPTCYP4F2CYP4A11CA12
SCHEMBL29356674 0.84 CA12 (0.35) GRIN2BNAMPTCYP4F2CYP4A11CA12
SCHEMBL24115980 0.81 NPC1 (0.36) PRMT5WDR77P2RX3
SCHEMBL9320759 0.78 GRIN2B (0.47) GRIN2BCYP4F2CYP4A11CHRNB4CHRNA3
SCHEMBL21893908 0.77 ESR1 (0.36) PRMT5WDR77P2RX3
SCHEMBL24253497 0.77 GABRA1 (0.39) PRMT5WDR77P2RX3
SCHEMBL2633408 0.76 GRIN2B (0.46) GRIN2BCHRNB4CHRNA3CHRNA7
SCHEMBL6988847 0.75 DRD2 (0.44) CA2CA5A
SCHEMBL21382504 0.74 PRMT5 (0.38) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 WO disclosed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 GRIN2B 2776/4885PRMT5 449/4885WDR77 1010/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 GRIN2B 2776/4885PRMT5 449/4885WDR77 1010/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 GRIN2B 2776/4885PRMT5 449/4885WDR77 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.